Abstract
Etodolac is a chiral non-steroidal antiinflammatory drug which inhibits cyclooxigenase-2(COX-2). It is clinically available as a racemic mixture of its two enantiomers: (S)-(+)-etodolac (S-ETO)and (R)-(-)-etodolac (R-ETO). The present study aims to evaluate the population pharmacokinetic-pharmacodynamic relantionship (PK-PD) of etodolac in healthy volunteers treated with racemic drug and …